You are here

Article Text

Article menu
Download PDFPDF
Coronary artery disease
Original research
Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction
  1. Lars Nepper-Christensen1,
  2. Dan Eik Høfsten1,
  3. Steffen Helqvist1,
  4. Jens Flensted Lassen1,
  5. Hans-Henrik Tilsted1,
  6. Lene Holmvang1,
  7. Frants Pedersen1,
  8. Francis Joshi1,
  9. Rikke Sørensen1,
  10. Lia Bang1,
  11. Hans Erik Bøtker2,
  12. Christian Juhl Terkelsen2,
  13. Michael Maeng2,
  14. Lisette Okkels Jensen3,
  15. Jens Aarøe4,
  16. Henning Kelbæk5,
  17. Lars Køber1,
  18. Thomas Engstrøm1,
  19. Jacob Lønborg1
  1. 1 Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  2. 2 Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark
  3. 3 Department of Cardiology, Catheterisation Lab, Odense University Hospital, Odense, Denmark
  4. 4 Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
  5. 5 Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark
  1. Correspondence to Dr Lars Nepper-Christensen; lars.nepper{at}gmail.com

Abstract

Objective The Third Danish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction – Ischaemic Postconditioning (DANAMI-3-iPOST) did not show improved clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) treated with ischaemic postconditioning. However, the use of thrombectomy was frequent and thrombectomy may in itself diminish the effect of ischaemic postconditioning. We evaluated the effect of ischaemic postconditioning in patients included in DANAMI-3-iPOST stratified by the use of thrombectomy.

Methods Patients with STEMI were randomised to conventional primary percutaneous coronary intervention (PCI) or ischaemic postconditioning plus primary PCI. The primary endpoint was a combination of all-cause mortality and hospitalisation for heart failure.

Results From March 2011 until February 2014, 1234 patients were included with a median follow-up period of 35 (interquartile range 28 to 42) months. There was a significant interaction between ischaemic postconditioning and thrombectomy on the primary endpoint (p=0.004). In patients not treated with thrombectomy (n=520), the primary endpoint occurred in 33 patients (10%) who underwent ischaemic postconditioning (n=326) and in 35 patients (18%) who underwent conventional treatment (n=194) (adjusted hazard ratio (HR) 0.55 (95%confidence interval (CI) 0.34 to 0.89), p=0.016). In patients treated with thrombectomy (n=714), there was no significant difference between patients treated with ischaemic postconditioning (n=291) and conventional PCI (n=423) on the primary endpoint (adjusted HR 1.18 (95% CI 0.62 to 2.28), p=0.62).

Conclusions In this post-hoc study of DANAMI-3-iPOST, ischaemic postconditioning, in addition to primary PCI, was associated with reduced risk of all-cause mortality and hospitalisation for heart failure in patients with STEMI not treated with thrombectomy.

Trial registration number NCT01435408.

  • percutaneous coronary intervention
  • acute coronary syndromes
  • acute myocardial infarction

https://doi.org/10.1136/heartjnl-2019-314952

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • TE and JL contributed equally.

    • Contributors Planning: TE, JL, LN-C, LK, SH, HK Conduct: All. Reporting: All. Overall responsible: TE.

    • Funding This work was supported by the Danish Agency for Science, Technology and Innovation, and the Danish Council for Strategic Research (Eastern Denmark Initiative to Improve Revascularisation Strategies (EDITORS), grant 09-066994).

    • Competing interests LK reports grants from Danish Research Foundation during the conduct of the study. TE reports personal fees from Boston Scitienfic, Abbott, Bayer, Novo Nordisk and Astra Zeneca outside the submitted work.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Correction notice Since this paper was first published online, Henning Kelbæk’s affiliation has been updated.

    • Patient consent for publication Not required.

    Linked Articles